Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
– Announces key appointments in oncology R&D and business development functions
– Cash and cash equivalents of $283 million expected to provide runway into 2026
Related news for (TERN)
- Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701
- Non-Alcoholic Steatohepatitis (NASH) Pipeline Insight Report, 2025 – Featuring Analysis of Inventiva Pharma, Cirius Therapeutics, Terns Pharmaceuticals, HighTide Biopharma, Eli Lilly and Company, and More
- Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
- Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference
- Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer